BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29795382)

  • 1. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
    Lehmann-Che J; Bally C; Letouzé E; Berthier C; Yuan H; Jollivet F; Ades L; Cassinat B; Hirsch P; Pigneux A; Mozziconacci MJ; Kogan S; Fenaux P; de Thé H
    Nat Commun; 2018 May; 9(1):2047. PubMed ID: 29795382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
    Iaccarino L; Ottone T; Alfonso V; Cicconi L; Divona M; Lavorgna S; Travaglini S; Ferrantini A; Falconi G; Baer C; Usai M; Forghieri F; Venditti A; Del Principe MI; Arcese W; Voso MT; Haferlach T; Lo-Coco F
    Am J Hematol; 2019 Oct; 94(10):1091-1097. PubMed ID: 31292998
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
    Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.
    Tong Q; You H; Chen X; Wang K; Sun W; Pei Y; Zhao X; Yuan M; Zhu H; Luo Z; Zhang Y
    Nucleic Acids Res; 2018 Apr; 46(7):3284-3297. PubMed ID: 29554366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
    J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
    Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
    Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
    Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
    Hattori H; Ishikawa Y; Kawashima N; Akashi A; Yamaguchi Y; Harada Y; Hirano D; Adachi Y; Miyao K; Ushijima Y; Terakura S; Nishida T; Matsushita T; Kiyoi H
    PLoS One; 2018; 13(10):e0204850. PubMed ID: 30289902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Iaccarino L; Ottone T; Hasan SK; Divona M; Cicconi L; Lavorgna S; Alfonso V; Basso G; Barragán E; Bocchia M; Rego EM; Grimwade D; Voso MT; Lo-Coco F
    Leuk Lymphoma; 2018 May; 59(5):1268-1270. PubMed ID: 28838264
    [No Abstract]   [Full Text] [Related]  

  • 12. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute promyelocytic leukemia with a cryptic insertion of RARA into TBL1XR1.
    Osumi T; Watanabe A; Okamura K; Nakabayashi K; Yoshida M; Tsujimoto SI; Uchiyama M; Takahashi H; Tomizawa D; Hata K; Kiyokawa N; Kato M
    Genes Chromosomes Cancer; 2019 Nov; 58(11):820-823. PubMed ID: 31350930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.
    Nichol JN; Galbraith MD; Kleinman CL; Espinosa JM; Miller WH
    Cell Rep; 2016 Mar; 14(12):2938-49. PubMed ID: 26997274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
    He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
    Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
    de Thé H; Pandolfi PP; Chen Z
    Cancer Cell; 2017 Nov; 32(5):552-560. PubMed ID: 29136503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy-induced secondary acute myeloid leukemia with t(11;19)(q23;p13.1) in a pediatric patient with relapsed acute promyelocytic leukemia.
    Dang DN; Morris HD; Feusner JH; Koduru P; Wilson K; Timmons CF; Cavalier M; Luu HS
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e546-8. PubMed ID: 24942021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
    Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
    Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
    Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
    Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
    Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.